Novo NordiskSee all their emails

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis

A real newsletter email from Novo Nordisk. Captured September 17, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis email from Novo Nordisk screenshot

Captured Newsletter

Novo Nordisk announces the publication of phase 3b results from the FRONTIER5 study of denecimig in the Journal of Thrombosis and Haemostasis.

Top-left corporate logo, followed by text-heavy layout featuring research data bullet points, press release paragraphs, multiple data tables, media contacts, and detailed reference links at the bottom.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.